Monday, January 06, 2025 10:01:24 AM
Well done?
How many got diluted?
Tough to say since GNPX doesn't report?
Loophole?
Nothing like a scam off the backs of Cancer?
Ryan Confer might be knowing frauding the public off the idea of Cancer?
What kind of low life does such a thing?
Rodney Varner the man with many names and many years of stick manipulation does suddenly and Ryan Confer takes over?
How deep does the pyramid scheme of GNPX go?
IMO
Everything I post, is In my own opinion, I don't care what you think about it, if you disagree, post it like I do. If you buy or sell stock based on what I say, your a lunatic and should not be trading. Have a great day!
Recent GNPX News
- Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/06/2025 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/20/2024 01:45:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2024 02:15:09 PM
- Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer • PR Newswire (US) • 12/16/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:55:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:53:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:50:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:48:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2024 02:29:11 PM
- Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer • PR Newswire (US) • 11/20/2024 02:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 10:15:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 02:16:53 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/08/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 02:29:40 PM
- Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 11/05/2024 02:29:00 PM
- Genprex to Participate in 2024 BIO Europe Conference • PR Newswire (US) • 10/31/2024 01:29:00 PM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma • PR Newswire (US) • 10/28/2024 01:29:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/24/2024 04:23:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 01:29:33 PM
- Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive • PR Newswire (US) • 10/24/2024 01:29:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/22/2024 04:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 01:29:57 PM
- Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer • PR Newswire (US) • 10/15/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 10/10/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 10/07/2024 01:29:00 PM
FEATURED EzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion • Jan 7, 2025 8:35 AM
Fifty 1 Labs, Inc. Launches Dedicated Website for Shareholders and Investors, Company now current with OTC Markets • CAFI • Jan 7, 2025 9:00 AM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM
UAV Corp (UMAV) Working on Securing $1.5 Billion in Contracts and Announces Groundbreaking Partnership with Atlantic Industrial Group • UMAV • Jan 6, 2025 9:26 AM
Basanite, Inc. to Open New Production and Distribution Facility in Northeast Ohio • BASA • Jan 2, 2025 8:28 AM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM